Sen. Scott Urges FDA to Address Gene Therapy Priority Voucher Discrepancy
October 25, 2024
October 25, 2024
WASHINGTON, Oct. 25 -- Sen. Tim Scott, R-South Carolina, issued the following news release:
In order to help increase treatment for sickle cell disease (SCD), U.S. Senator Tim Scott (R-S.C.) penned a letter to the Food and Drug Administration (FDA) Commissioner Robert Califf raising concerns over how the FDA interprets "active ingredient" for awarding priority review vouchers, which could negatively impact drug development for rare diseases like sickle cell disease. Senato . . .
In order to help increase treatment for sickle cell disease (SCD), U.S. Senator Tim Scott (R-S.C.) penned a letter to the Food and Drug Administration (FDA) Commissioner Robert Califf raising concerns over how the FDA interprets "active ingredient" for awarding priority review vouchers, which could negatively impact drug development for rare diseases like sickle cell disease. Senato . . .